Vitamin D3 Inhibits SARS-CoV-2 Nucleocapsid Induced Hyperinflammation By Inactivating NLRP3 Inflammasome Via The VDR-BRCC3 Pathway
Medical News - Vitamin B3 Inhibits SARS-CoV-2 Nucleocapsid Induced Hyperinflammation Jun 26, 2023 1 year, 5 months, 3 weeks, 5 days, 19 hours, 41 minutes ago
Medical News: Vitamin D3 Discovered To Inhibit COVID-19 Hyperinflammation by Targeting Key Protein
Medical News: In a new study conducted at the Army Medical University in Chongqing, China, researchers have uncovered a potential game-changer in the fight against COVID-19. The study reveals that Vitamin D3, commonly known for its health benefits, has the remarkable ability to attenuate hyperinflammation caused by the SARS-CoV-2 nucleocapsid protein.
.jpg)
The study team further explain that this effect is achieved through the inactivation of a specific protein complex known as the NLRP3 inflammasome, acting via the VDR-BRCC3 signaling pathway.
The study sheds light on the mechanisms underlying the therapeutic potential of Vitamin D3 in combating the severe inflammatory responses observed in COVID-19 patients. The excessive release of proinflammatory cytokines, often referred to as the "cytokine storm," is a major contributing factor to the acute respiratory distress syndrome seen in severe cases of COVID-19.
Previous studies and
Medical News reports have highlighted the relationship between Vitamin D3 levels and the risk of SARS-CoV-2 infection. Low levels of Vitamin D3 have been associated with an increased susceptibility to the virus. In this context, the researchers aimed to investigate the exact effects of Vitamin D3 on SARS-CoV-2 infection and its underlying mechanism.
The NLRP3 inflammasome, a key component of the innate immune system, plays a crucial role in regulating inflammatory responses. Its activation leads to the secretion of interleukin-1 beta (IL-1β), a proinflammatory cytokine implicated in various inflammatory diseases, including COVID-19. The study team discovered that the SARS-CoV-2 nucleocapsid protein triggers NLRP3 inflammasome activation, resulting in excessive inflammation. However, they found that Vitamin D3 effectively inhibits NLRP3 inflammasome activation induced by the nucleocapsid protein, thus curbing hyperinflammation.
To unravel the underlying mechanism, the scientists explored the interactions between Vitamin D3, the NLRP3 inflammasome, and the VDR-BRCC3 signaling pathway. Their findings revealed that Vitamin D3 increases the expression of Ub-NLRP3, a form of NLRP3 modified by ubiquitin, while reducing the levels of BRCC3, a protein involved in NLRP3 deubiquitination. Vitamin D3 also enhances the binding of the Vitamin D receptor (VDR) with NLRP3, preventing its association with BRCC3 and subsequent deubiquitination. These effects ultimately lead to the inactivation of the NLRP3 inflammasome and the attenuation of hyperinflammation.
The study team conducted experiments both in vitro, using human bronchial epithelial cells, and in vivo, with mice infected with a viral protein. In both cases, Vitamin D3 demonstrated its ability to inhibit hyperinflammation caused by the SARS-CoV-2 nucleocapsid protein, further validating its potential as a therapeutic agent against COVID-19.
The implications of this study are significant, particularly in the absence of satisfactory treatment options for severe COVID-19 cases. Vitamin D
3 supplementation has already been recognized as a promising strategy for reducing the risk and severity of COVID-19, with several studies highlighting its potential benefits. This latest research provides direct evidence of Vitamin D3's efficacy in combating the disease and offers valuable insights into its underlying mechanisms.
As the world continues to battle the COVID-19 pandemic, the discovery of Vitamin D3's ability to modulate the hyperinflammatory response caused by the SARS-CoV-2 nucleocapsid protein holds great promise for the development of targeted therapies. The findings suggest that Vitamin D3 supplementation could potentially help mitigate the severe inflammatory complications associated with COVID-19, leading to improved patient outcomes.
Further research is warranted to explore the optimal dosage, duration, and timing of Vitamin D3 supplementation in COVID-19 patients. Clinical trials involving larger patient populations are needed to validate these findings and assess the efficacy of Vitamin D3 as an adjunctive treatment for severe cases.
The study findings were published in the peer reviewed journal: MedComm (Wiley)
https://onlinelibrary.wiley.com/doi/10.1002/mco2.318
For the latest
Medical News, keep on logging to Thailand Medical News.
Share
Tweet
Share
